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Background: Ectopic pregnancy (EP) is the leading cause of maternal morbidity and mortality during the first
trimester and the incidence increases dramatically with in vitro fertilisation and embryo transfer (IVF-ET). The
co-existence of an EP with a viable intrauterine pregnancy (IUP) is known as heterotopic pregnancy (HP) affecting
about 1% of patients during assisted conception. EP/HP can cause significant morbidity and occasional mortality
and represent diagnostic and therapeutic challenges, particularly during fertility treatment. Many risk factors
related to IVF-ET techniques and the cause of infertility have been documented. The combination of transvaginal
ultrasound (TVS) and serum human chorionic gonadotrophin (hCG) is the most reliable diagnostic tool, with early
diagnosis of EP/HP permitting conservative management. This review describes the risk factors, diagnostic modalities
and treatment approaches of EP/HP during IVF-ET and also their impact on subsequent fertility treatment.
Methods: The scientific literature was searched for studies investigating EP/HP during IVF-ET. Publications in English
and within the past 6 years were mostly selected.
Results: A history of tubal infertility, pelvic inflammatory disease and specific aspects of embryo transfer technique are
the most significant risk factors for later EP. Early measurement of serum hCG and performance of TVS by an expert
operator as early as gestational week 5 can identify cases of possible EP. These women should be closely monitored
with repeated ultrasound and hCG measurement until a diagnosis is reached. Treatment must be customised to the
clinical condition and future fertility requirements of the patient. In cases of HP, the viable IUP can be preserved in the
majority of cases but requires early detection of HP. No apparent negative impact of the different treatment
approaches for EP/HP on subsequent IVF-ET, except for risk of recurrence.
Conclusions: EP/HP are tragic events in a couple’s reproductive life, and the earlier the diagnosis the better the
prognosis. Due to the increase incidence following IVF-ET, there is a compelling need to develop a diagnostic
biomarker/algorithm that can predict pregnancy outcome with high sensitivity and specificity before IVF-ET to
prevent and/or properly manage those who are at higher risk of EP/HP.
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Ectopic pregnancy (EP) is a form of abnormal preg-
nancy in which the fertilised ovum implants outside the
intrauterine cavity, with the ampullary region of the
Fallopian tube being the most common site of implant-
ation (Figure 1) [1]. EP represents 1-2% of all pregnancies
and haemorrhage from an EP due to tubal rupture re-
mains the most common cause of maternal mortality in
the first trimester of pregnancy [2].
Infertility is a problem affecting 8-12% of couples
worldwide [3]. The associations between infertility and
EP are complex, as one of them could be simultaneously
a cause and the other a consequence [4,5]. There is an
increased risk of developing EP following fertility treat-
ment, which could be due to the effects of the treatment
or the pre-existing disorder [6].
Since the birth of the first successful in vitro fertilisation
(IVF) baby in 1978 [7], there has been an increase demand
for assisted reproductive technologies (ART), including
intrauterine insemination and IVF-embryo transfer
(IVF-ET) with or without intracytoplasmic sperm injec-
tion [8]. Nevertheless, IVF-ET is a major risk for the
development of EP and the incidence is greater by 2–3
folds than that seen in the general population. IVF may
also result in a heterotopic pregnancy (HP), which is an
EP together with a viable intrauterine pregnancy (IUP) [6].
Several factors related to the cause of female infertility
and applied technical procedures during IVF-ET have
been described as major risk factors for EP/HP. The
current review discusses these risk factors, available
diagnostic modalities and management approaches for
the treatment of EP/HP following IVF-ET treatment,













Figure 1 Sites and prevalence of ectopic pregnancy following IVF-ET.treatment on the chances of success of subsequent fertility
treatment.
Methods
‘Medline’ and ‘EMBASE’ were searched using the terms
‘in vitro fertilisation’, ‘embryo transfer’, ‘controlled ovarian
stimulation’, ‘risk factors’, ‘diagnosis’, ‘ultrasound’, ‘human
chorionic gonadotropin’, ‘laparotomy’, ‘laparoscopy’, ‘salpin-
gectomy’, ‘salpingostomy’, ‘methotrexate’, ‘potassium chlor-
ide’, ‘hyperosmolar glucose’, ‘vasopressin’, ‘embryo reduction’,
‘ovarian reserve’ and ‘pregnancy rate’ in combination with
‘ectopic pregnancy’, ‘heterotopic pregnancy’, ‘tubal preg-
nancy’, ‘interstitial pregnancy’, ‘ovarian pregnancy’, ‘caesarean
scar pregnancy’, ‘cervical pregnancy’ or ‘abdominal preg-
nancy’ for studies published between 2004 and 2014.
Publications in English and within the past 6 years were
selected, but commonly referenced and important older
publications were not exclude. The reference lists of arti-
cles identified by this search strategy were also searched
and those judged as relevant were also included. For a
study to be included, it needed to be focused on incidence,
diagnosis, clinical management and effect on subsequent
IVF cycle of EP/HP during IVF-ET treatment. Studies that
were solely focusing on EP following spontaneous concep-
tion were not included except of the management of HP
due to its infrequency.
Results
Prevalence
EP is estimated to be 1-2% of all natural conceptions and
the incidence increases following ART [4]. The prevalence
of EP following ART ranges between 2.1 to 8.6% of all
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EP has been reported to represent 5% and 10% of all
maternal deaths in developed and developing countries,
respectively [2].
Spontaneous HP was considered to be very rare with
an incidence of 1 in 30,000 pregnancies. The incidence
of HP has also increased following ART and it has been
reported that it complicates about 0.8% of pregnancies
following infertility treatment [10].
Pathogenic mechanisms
Tubal pregnancies that occurring naturally and following
IVF-ET share the same tubal risk factors, suggesting that
tubal damage has a predominant role in the pathogenesis
of both [6]. The proposed pathogenic mechanisms associ-
ated with risk factors for EP either following natural or
assisted conception are summarized in Figure 2.
Our understanding of the pathophysiology of EP is lim-
ited [11,12]. The current literature supports the hypothesis
that the major cause of tubal implantation is malfunction
of the tube itself, although embryonic and uterine factors
may also be implicated. Tubal malfunction results fromFigure 2 Pathogenic mechanisms. Potential mechanisms involved in the p
relation to established risk factors.alterations in tubal transport mechanisms and expression
of molecules that normally inhibit blastocyst implantation
in the Fallopian tube [13-15].
However, in the case of EP post IVF-ET, in which pas-
sage of the embryo along the Fallopian tube does not
occur, additional factors that prevent intrauterine implant-
ation must precede ectopic implantation of the embryo.
Differentiating between the mechanisms involved in nat-
ural and post IVF-ET tubal pregnancy is difficult. To our
knowledge, only one study has compared tubal pathology
in natural and IVF ectopic pregnancies, using E-cadherin
as a marker of implantation potential [16]. Further bio-
logical studies using this comparative approach are neces-
sary in order to elucidate the mechanisms involved.
Another explanation for EP during IVF-ET would be
impairment of tubal function and endometrial receptivity
with ectopic implantation occurring following failure of
the normal biological interactions between endometrium,
Fallopian tube and embryo due to controlled ovarian
stimulation (COS) and the subsequent alteration in hor-
monal milieu [17,18]. Hence women with underlying tubal
disease undertaking IVF may face a “double whammy” inathogenesis of tubal pregnancy after natural and IVF conception, in
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of superovulation on tubal function during the IVF cycle.
Risk factors
Several factors increase the risk of EP following IVF-ET
and they are associated either with the infertility history
of the patient or specific factors related to IVF-ET tech-
niques (Table 1).
Factors related to infertility history
The increase in the incidence of EP is associate with the
use of ART. Even with a single embryo transfer, women
undergoing ART treatment have a relative risk of 6.40
(95% CI: 4.38-9.35) of developing EP compared with nat-
ural conceptions [19]. The increase in EP has been associ-
ated with several maternal risk factors, mainly related to
the woman’s infertility history.
Maternal age
Several research groups have shown that the risk of EP
increases with advancing age, particularly in women over
35 years [20,21]. A steady increase was also reported in
the incidence of EP with the increase in maternal age at
conception from 1.4% at the age of 21 years to 6.9% in
women aged 44 years or more [22]. An explanation for
this trend with age could be the existence of a higher
probability of exposure to most other risk factors with
advancing age, increase in chromosomal abnormalitiesTable 1 Risk factors for EP during IVF-ET
Maternal IVF-ET Technique
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Summary of definite and inconclusive risk factors for ectopic/heterotopic
pregnancy during in vitro fertilisation and embryo transfer treatment.in trophoblastic tissue and age-related changes in tubal
function [21].
Alternatively, other research groups have failed to detect
an association between maternal age and the risk of devel-
oping EP [23-25], Further prospective studies with large
numbers of participants are needed to determine whether
a relation truly exists between maternal age and the risk of
developing EP during IVF-ET.
Tubal factor infertility
Tubal factor infertility (TFI) is a major risk for EP when
compared to other causes of infertility [6,26]. IVF-ET
was originally designed to overcome TFI by placing the
embryo(s) within the uterine cavity. However, it appears
that the embryo, in some cases, can still enter the tube
and establish an ectopic implantation [20].
TFI, compared with other causes of infertility, in-
creases the risk of EP following IVF-ET with a preva-
lence of up to 11% of cases with TFI [9]. Similar results
were also reported by a more recent study that exam-
ined the risk factors for EP following IVF in 712 women
with an OR of 3.99 (95% CI: 1.23 to 12.98) for women
with TFI compared with those with other infertility
causes [23]. Another study has also described that the
OR for EP in 900 women with planned pregnancy was
8.81 (95% CI: 1.68–21.21) for those with a history of TFI
compared with 5.82 [95% CI: 3.47, 9.78] for non-tubal
infertility. However, the authors have also reported that
the adjusted odd ratio (AOR) was comparable between
TFI (3.62; 95% CI: 1.52, 8.63) and non-TFI (3.34; 95%
CI: 1.60, 6.93) [25].
Pelvic Inflammatory Disease
A history of pelvic inflammatory disease (PID) has also
been implicated in the increased incidence of EP follow-
ing either natural or assisted conception [26,27]. A past
history of PID is associated with a 7.5 times greater risk
of developing EP [28,29].
Chlamydia trachomatis infection is the most common
sexually transmitted infection worldwide [30,31]. The
immune response to this infection may lead to tubal oc-
clusion, EP and infertility [27,32,33]. Despite spontan-
eous clearance of C. trachomatis infection, antibodies
against the organism and its heat shock protein-60
(CHSP60) remain detectable for many years. The pres-
ence of these antibodies have been strongly associated
with poor reproductive outcomes, including early preg-
nancy loss and EP following IVF [25,32].
The presence of IgA antibodies against Chlamydia tra-
chomatis was associated with lower implantation and
pregnancy rates among 235 patients undergoing IVF
[34]. Live birth rate following IVF was also found to be
lower in women with cervical anti-chlamydial and anti-
CHSP60 IgA antibodies when compared with those who
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were also observed for an effect on implantation rate in
253 IVF patients with follicular fluid anti-CHSP60 anti-
bodies [35]. This is further supported by a more recent
study that has shown that the risk of EP in 900 women
with planned pregnancies and who had detectable C.
trachomatis IgG was about five times of those with
negative reaction (95% CI: 3.94–7. 04) [25].
In contrast, other studies have not supported a role for
previous infection with C. trachomatis in the develop-
ment of EP [23,36,37]. One longitudinal study found that
there was no significant difference in pregnancy rates for
women with or without chlamydial infection at baseline
[38]. Similar results were also reported for 712 IVF pa-
tients [23]. The presence of antibodies against CHSP60
among 174 women with apparently normal Fallopian
tubes at laparoscopy was also not associated with lower
pregnancy rates during 3 years follow-up [39]. A recent
review has therefore suggested that the inconsistency in
the results could be related to flaws in study design and
lack of a reliable method for measuring a history of pelvic
infection [13]. The authors also argued that the current
assumptions on the risks of adverse outcomes following
pelvic infection in subsequent pregnancy are based on
retrospective case–control studies, which are prone to
many confounding variables [13].
Previous ectopic pregnancy
A history of EP is considered as a major risk factor for
subsequent recurrence of EP and each successive occur-
rence significantly increases the risk [5,22]. The recur-
rence rate ranges from 15 to 20% in the case of one
previous EP treated by linear salpingostomy, depending
on the integrity of the contralateral tube and it increases
to 32% in cases with two previous ectopic pregnancies.
However, an intervening IUP lowers this rate [6,20,40].
A retrospective study measured the risk of EP following
IVF in 181 women with a previous ectopic, with signifi-
cantly higher risk of recurrence when compared with 377
women with other causes of infertility. The authors re-
ported that the chance of developing EP was 45 times
in the case group and the prevalence of EP was 8.95%
compared with 0.75% in the control group [24]. Similar
results with an OR of 9.68 (95% CI: 6.02-15.56) for
were reported in a study of 900 EPs compared with 889
IUPs in women with planned pregnancy [25] and another
study also demonstrated an OR of 57.93 (95% CI: 6.79-
494.25) for developing EP in 150 women diagnosed with
EP compared with 300 healthy pregnant women [21].
Previous tubal surgery
A history of tubal/pelvic surgery is another major risk
factor for the development of EP following IVF, with
the level of risk depending on the degree of damageand the extent of anatomic alteration [6,22]. Odds ratio
for developing EP was 8.52 (95% CI: 5.91-12.27) for
prior adnexal surgery, 11.02 (95% CI: 5.49, 22.15) for a
previous tubal infertility surgery, 5.16 (95% CI: 1.25-
21.21) for prior surgery for endometriosis and 17.70
(95% CI: 8.11-38.66) for a previous abdominal/pelvic
surgery [21,23,25].
Hydrosalpynx is a main cause of tubal infertility and is
also associated with a negative impact on the outcome
of IVF treatment. Treatment of hydrosalpynx before IVF
involves radical and conservative surgical approaches
[41,42]. The rate of EP has been reported to be about
9% in patients undergoing IVF following tubal surgery
for the treatment of hydrosalpinx [43,44].
Endometriosis
Endometriosis and its treatment has also been associated
with the development of EP [6,25,45]. Endometriosis leads
to the formation of pelvic and tubal adhesions, which
could result in abnormal tubal function. Additionally, the
Fallopian tubes could also be affected by other, less clearly
understood effects of endometriosis [46,47], as well as by
the medications that are administered to aid ovulation and
improve fertility in patients with endometriosis [23].
Cigarette smoking
Cigarette smoking increases the risk of EP after natural
conception by 1.6 to 3.5 times as compared to non-
smokers, in a dose dependant manner [25,48,49]. Smokers
also have a higher risk of developing EP following IVF treat-
ment of about 3 times compared with non-smokers
[24,25,49]. Laboratory studies in several species have shown
that smoking decreases tubal and uterine motility [50-53].
Uterine abnormalities
Studies of the uterine factors that may be implicated in
EP after IVF-ET have focused on the mechanism by
which the embryo migrates into the Fallopian tube after
intrauterine transfer. The possible effects of uterine ab-
normalities on implantation failure have not been well
studied to date. A recent meta-analysis [54] concluded
that “there is very little evidence that the established
treatments improve outcomes, or that these pathologies
have a negative effect on ART”. One study has reported
that intramural fibroids are associated with a higher fre-
quency of uterine peristalsis in the peri-implantation
phase [55] but further work is required. The impact of
uterine pathologies on risk of EP after IVF-ET remains
to be elucidated.
Infertility treatment specific risk factors
An increased incidence and unusual forms of EP have
been reported after IVF-ET and, in fact, the first preg-
nancy reported after IVF-ET was an EP [56]. Several
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IVF-ET and many technical issues of the treatment have
been proposed as risk factors for EP. These risk factors
(Table 1) include an altered hormonal milieu due to
COS, the day and stage of embryo transfer, multiple em-
bryo transfer, volume of transfer media and position of
the catheter.
Controlled ovarian hyperstimulation
The alteration in the endocrine milieu in the stimulated/
fresh cycle following COS may be a potential risk factor
for the development of EP during IVF-ET. Possible
mechanisms involve diminished endometrial receptivity
[6], which could be supported by the observations that
endometrial and subendometrial blood flow on the day
of human chorionic gonadotropin (hCG) injection were
significantly lower in IVF patients with miscarriage and
EP when compared with those with viable IUP [57].
Higher circulating concentrations of oestradiol (E2)
during stimulated cycles could also be associated with a
reverse migratory process of the transferred embryo(s)
[58]. A recent retrospective study showed that COS in
patients with polycystic ovarian syndrome (PCOS) was
associated with a greater risk of EP in fresh cycles (AOR
3.06; 95% CI: 1.34-6.96) but not with frozen-thawed em-
bryo transfer (FTE) cycles. By further analysing the cases
of EP in the non-PCOS patients, women with E2 levels
> 4085 pg/mL had 2 times greater risk of developing EP
(95% CI: 1.19-3.35). Hence, the authors suggested that
the observed higher prevalence of EP during COS could
be related to the hyperphysiologic levels of E2 associated
with PCOS and/or ovulation induction [59].
Another review has suggested that the increased con-
centrations of progesterone in stimulated cycles could
be beneficial in promoting endometrial implantation by
decreasing uterine contractions when compared with
FET cycles [6]. However, a later meta-analysis has identi-
fied a lack of randomised controlled trials (RCTs). The
authors recommended the conduct of appropriately
powered RCTs to compare natural cycle IVF with stand-
ard IVF, with outcomes including adverse events such as
EP [60].
Available information on the possible effect of luteal
phase support during the fresh cycle or for endometrial
preparation in FET cycles in relation to the develop-
ment of EP is conflicting. A retrospective study has
shown that patients with high circulating concentra-
tions of oestrogen and progesterone on the day of hCG
injection had the highest frequency of EP compared
with the low E2 and low progesterone groups [61].
Similar observations were also reported by other retro-
spective studies showing that programmed FET cycles
were associated with higher rates of EP compared with
natural cycles [62,63].Conversely, a retrospective analysis of 1677 FTE cycles
showed a non-significant difference in the prevalence of
EP in natural versus programmed cycles [64]. This was
supported by later data generated from an RCT and two
retrospective studies that revealed no significant differ-
ences for use of progesterone in FET cycles in EP rates
[65-67]. Several other multicentre RCTs have also mea-
sured the effect of different progesterone preparations
for luteal phase support in fresh and FET cycles with no
significant differences in the prevalence of EP [68-70].
Similar results were also reported by two recent meta-
analyses including 91 RCTs of luteal phase support with
progesterone or hCG [71,72].
In a prospective case–control study that included 100
IVF-ET cycles, a non-significant increasing trend in the
prevalence of EP was observed between the use of
GnRH-agonist in combination with hCG for triggering
oocyte maturation compared with use of hCG alone
[73]. A different retrospective study has described the
opposite effect, with significantly higher rates of EP with
GnRH-agonist trigger (5.3%) compared with recombin-
ant hCG (1.4%) for oocyte maturation [74]. However, a
recent Cochrane review has concluded that there is a
lack of evidence that either treatment used for final oocyte
maturation is associated with an increased risk of develop-
ing EP [75].
The association between COS and EP is still unclear and
the results of the aforementioned studies are contradict-
ory. The currently available data on the risk of developing
EP following COS are mainly derived from retrospective
studies or prospective case–control studies, which do not
provide high quality scientific evidence for the suggested
association between COS and EP. This has been reflected
in the conclusions of several systematic reviews that have
evaluated the different hormones during ART with the
authors consistently stating that there is a lack of high
quality evidence from RCTs that include the rate of EP
in their primary or secondary objectives.
The recent concept of ‘individualised COS’ protocol
that best fit the needs of each patient [76] makes the
analysis of a possible association between COS and EP
out with RCTs even more difficult. Future large multi-
centre RCTs with control for confounding variables are
still needed to reach a solid conclusion on whether COS
is a risk factor for the development of EP.
Embryonic factors
Assisted hatching (AH) has been proposed as a risk factor
for developing EP after IVF [6]. In a previous retrospective
analysis of 623 clinical pregnancies following IVF, a 5.4%
rate of EP (14/258) was found in cases where AH was per-
formed compared to 2.2% (8/365) in the non AH group
[77]. However, a more recent RCT showed that AH nei-
ther improved pregnancy rate nor increased risk of EP in
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analysis of 1126 AH cycles also reported that there was
no effect on the prevalence of EP in an antibiotic and
steroid treatment group compared with an untreated
group [79]. It may be worthwhile to assess the effect of
AH on the incidence of EP in a large multicentre study
but recent evidence is against such an association.
Embryo transfer at the blastocyst stage appears to be
the most biologically appropriate stage for intrauterine
implantation as earlier stages of embryo development
occur normally within the Fallopian tube [80]. Blastocyst
transfer may also theoretically decrease the incidence of
EP following IVF-ET as there may be decreased uterine
contractility by day five after egg collection [81,82].
However, the potentially higher implantation rate per
embryo at the blastocyst stage may increase the risk of
EP compared with cleavage stage transfer [6] but a num-
ber of studies have indicated that, in practice, there is no
difference in the incidence of EP between blastocyst and
cleavage stage transfers [80,82,83]. EP rates have also
been compared between frozen and fresh transfers of
blastocyst with frozen transfer being shown to have the
potential to decrease the frequency of EP compared with
fresh transfer [62,66,84-86].
The ‘quality’ of the embryo may also contribute to risk
of EP after IVF. Egg related factors such as chromosomal
abnormalities may increase risk of EP [87] and, in a ro-
dent study using an embryo donation model, superovu-
lation with gonadotropins was suggested to impair
blastocyst quality as well as endometrial receptivity [88].
A poor quality embryo may be less likely to undergo
eutopic implantation resulting both in a decrease in the
chances of establishment of an IUP and also increase in
risk of EP.
Other possible embryonic factors that could induce EP
following IVF include abnormal expression of adhesion
molecules either by embryos fertilised in vitro or from
tubal implantation sites following COS [16]. The abnormal
expression has been attributed to the exposure of embryo
(s) to different cytokines and growth factor milieu during
in vitro culture compared with embryos conceived in vivo
[13,16]. However, more sophisticated array studies are
needed to explore possible altered expressions at the gene
and protein levels by embryos following in vitro fertilisa-
tion and/or maturation.
Transfer technique
Another explanation for the development of EP following
IVF-ET has been related to the induction of abnormal
uterine contractions that may result in reverse migration
of embryos from the uterine cavity into the Fallopian tube
and ectopic implantation. Lesny et al. studied junctional
zone uterine contractility during mock embryo-transfers
and they reported that when the catheter was deliberatelyallowed to contact the uterine fundus, strong random con-
traction waves were observed in the fundal area and fluid
was moved directly into the Fallopian tubes [89,90].
Another recent study has also demonstrated that uterine
peristalsis increased significantly following 30 minutes of
mock ET during the luteal phase of natural cycle in 112
infertile women. The fluid movement was positively and
significantly correlated with the frequency of uterine peri-
stalsis and the fluid was moved to the cervix, Fallopian
tube and extruded in 5 (4.5%), 11 (9.8%) and 2 (1.8%)
patients, respectively. The same research group later
published another study on uterine peristalsis before
ET in 292 infertile women undergoing fresh and FET
cycles. Consistently, there was a significant negative
correlation between uterine contractions and the
achievement of clinical pregnancy. Moreover, uterine peri-
stalsis > 2 waves/minute was a major risk factor for not
achieving clinical pregnancy (OR 0.49; 95% CI: 0.34-0.70).
The authors have therefore suggested that high uterine
peristalsis could adversely affect embryo implantation and
lead to low implantation rate and/or EP [91,92].
The technique of ET could also influence the rate of
ectopic implantation due to forcing the embryo through
tubal ostia by hydrostatic pressure or by using large volume
of transfer medium [93-95]. Marcus et al. observed that pa-
tients having EP received a higher volume of culture
medium than those having normal IUP [96]. Knutzen et al.
also showed that after injecting 50 μl of radio-opaque fluid
through a standard ET catheter, the material was passed
either totally or partially into the Fallopian tubes in
44% of patients, suggesting that the chance of the em-
bryo being carried into the tube immediately after high
volume transfer [97].
The position of transfer catheter and the distance from
the fundal endometrium to either the tip of catheter or
to an air bubble within the catheter have also been in-
vestigated as potential risk factors for low pregnancy rate
and development of EP. An RCT showed that IUP fol-
lowing deep fundal transfer was 12.4% per cycle with a
1.5% EP versus 14.2% IUPs per cycle with a 0.4% ectopic
rate after midfundal transfer. The midfundal technique
was suggested to be superior because of a lower risk of
EP without any reduction in IUP rate [94,95]. This has
been further supported by Coroleu et al. (2002) who re-
ported that the placement of the transfer catheter close
to the fundus endometrial surface (1 cm) resulted in EP
while at a distance of 15–20 millimetres from the fundus
achieved higher implantation and pregnancy rates [98].
Others have recommended performing ET in a pos-
ition in which the fundus is at the highest point above
the horizon and to perform the transfer slowly over at
least 10 seconds [99]. They also suggest that placement
of the catheter tip near the fundus appeared to transfer
the embryos into the tube when transfer was performed
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of embryos to a standard midcavity position results in a
lower EP rate [99].
However, recent reports have also suggested that an op-
timal transfer location of a distance < 10 mm and > 5 mm
from the fundal endometrium results in higher pregnancy
rates compared with groups where the tip of the transfer
catheter was placed further from the fundus. There were
no cases of EP [100-102].
Multiple embryo transfer has always been associated
with increased risk of EP with transfer of two or less em-
bryos carrying lower risk than after three or more [103].
The current guidelines on the number of embryos to
transfer, which are based on the maternal age, could
therefore decrease the incidence of EP following IVF espe-
cially in younger patients with a single embryo transfer
[103,104]. Remarkably, a single elective embryo transfer is
associated with higher risk of EP (RR 6.40; 95% CI: 4.38-
9.35) compared with spontaneously conceived singletons
as reported by a recent meta-analysis [19]. Furthermore, a
recent study by Chai et al. (2014) has shown that there
was no significant difference in the frequency of EP be-
tween 74 women with single embryo transfer (2.5%) when
compared with 132 women with double embryo transfer
(5.2%) [105]. Nevertheless, single embryo transfer should
be the preferred choice for all patients under 40 as it
reduces risk of pregnancy complications, most notably
premature birth with risk of subsequent impairment of
the health of the offspring [106,107].Diagnosis of EP/HP following IVF-ET
EP/HP are serious complications during ART and
present considerable diagnostic and therapeutic chal-
lenges. Adverse maternal outcomes may follow rupture
of the EP with hypovolemic shock and blood transfusion
requiring [10,14,108]. These events may also adversely
affect the viable IUP in the case of HP. A single deter-
mination of serum hCG, even as early as 11–12 days
after ET, and early transvaginal ultrasound (TVS) have
been found to be predictive of pregnancy location
[109,110] but cannot reliably identify a viable IUP with a
co-existing EP.Diagnostic modalities of EP
Serial quantitative measurement of hCG in combin-
ation with TVS is the currently accepted paradigm for
clinical diagnosis and management of EP, with hCG
monitoring being used to follow patients until complete
resolution of the EP [4,5,111,112]. TVS can effectively
detect small intrauterine and ectopic pregnancies when
serum hCG level is 2000 IU/L [4,5,112] due to its superior
resolution [111,113].Human chorionic gonadotropin (hCG)
Although ART procedures and/or the pre-existing disorder
may affect the course of hCG concentration [114], several
studies on IVF patients have reported that a single serum
β-hCG assay can accurately differentiate between viable
and non-viable pregnancies. However, threshold values
vary between the different studies, depending mainly on
the exact day of the assay in relation to the date of ET.
Measuring serum concentrations of β-hCG in the
peri-implantation period (day 5 post blastocyst transfer)
was highly predictive of IVF-ET outcome and was able
to differentiate ongoing pregnancies from failing preg-
nancies, including EP [115]. Another retrospective study
showed that serum β-hCG on day 12 post ET for the
diagnosis of EP had a sensitivity of 82.7%, specificity of
71.1%, positive predictive value (PPV) 15.5% and nega-
tive predictive value (NPV) 98.5% at a cut-off of 91 IU/L
[110]. Similar results were also reported in 177 IVF cy-
cles using 80 mIU/mL as the cut-off for a positive test
result yielded a 94% sensitivity, 53.4% specificity and
80% positive predictive value for live birth [116]. Serum
levels of β-hCG on day 15 following oocyte retrieval
were shown to be dependent on the day of ET, being sig-
nificantly higher after day 5 (198 ± 10.6 IU/L) compared
with day 3 (103.6 ± 4.4 IU/L) transfers. The authors also
reported that serum β-hCG above 78 IU/L and 160 IU/L
were highly predictive of ongoing pregnancy for day 3 and
day 5 transfers, respectively [117]. Another retrospective
study showed that serum β-hCG at a cut-off value of
377.8 IU/L on day 17 post oocyte collection generated an
area under the curve of 0.730 with 75.9% sensitivity and
61.2% specificity for the diagnosis of EP [118].
Ultrasound
Ultrasound can be used to locate a pregnancy anatomic-
ally and to see if the fetus is alive. In general, a gestational
sac can be consistently identified by TVS at a cut-off level
of serum β-hCG is 2000 IU/L, which is known as the
discriminatory zone [119,120].
The finding of an empty uterine cavity can be associated
with a small early pregnancy, EP or miscarriage. The cor-
relation of the sonographic finding with serum level of
hCG is therefore useful for achieving accurate diagnosis. If
β-hCG level is below the discriminatory level, measure-
ment of the hormone should be repeated every 48 hours
with a repeat ultrasound when the level has reached the
predetermined discriminatory level [121]. However, if the
β-hCG is above the predetermined threshold or if it stabi-
lises/fails to increase normally, then the diagnosis of an EP
needs to be considered [121,122].
Diagnosis of HP
HP is a rare but potentially life-threatening event and
early diagnosis and treatment are essential in order to
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and mortality [122,123]. Hence this challenging condition
should be suspected in all patients who conceive following
ART regardless of the presence or absence of currently
recognised risk factors, particularly after transfer of mul-
tiple embryos. Investigation of the adnexa by TVS is es-
sential to exclude the possibility of HP. A moderate or
large amount of free pelvic fluid should warrant particular
care when assessing the adnexa with ultrasound, even in
the presence of an IUP [124,125].
The diagnosis of HP is elusive and challenging due to
the co-existence of the viable IUP which can generate an
appropriate increase in the level of β-hCG. Thus the
diagnostic value of hCG measurement is limited in cases
with HP and the diagnosis is mainly dependent on the
findings of TVS [122,124]. In a retrospective study that
included a total of 184 HP following IVF-ET, 174 were
diagnosed by TVS while 10 cases were missed. The three
main types of ultrasonographic findings were: visualisa-
tion of extrauterine gestational sac in 57.3%, adnexal
mass in 25.4% and ring sign in 17.2% of cases. The sensi-
tivity and specificity of TVS in the diagnosis of HP was
92.4% and 100% respectively with positive and negative
predictive values of 100% and 99.9%, respectively [126].
Most cases of HP are missed on initial presentation,
which could be due a false sense of security provided by
the sonographic finding of a viable IUP with failure to
inspect the adnexa fully or the HP being too small to
identify [122]. The amount of fluid in the cul-de-sac can
assist in the diagnosis of HP. One study found that pa-
tients with abnormal cul-de-sac fluid were five times
more likely to have HP as patients without it [127].
Causes of misdiagnosis include misidentification of an
HP as a corpus luteal cyst [122,127] or due to mirror
image artefact on TVS due to the patient having a full
bladder during the process, which causes reflection of a
viable IUP on a different part of the image and could be
mistakenly diagnosed as HP [128].
A retrospective study investigated 28 EP/HP that rup-
tured due to misdiagnosis and/or delayed management
and the main factors that led to delay were insufficient
training in TVS and unawareness about EP/HP by the
physicians, atypical symptoms and early rupture of EP.
The authors suggested that TVS should therefore be per-
formed at week 5 of gestation followed by serial measure-
ment of serum β-hCG and repeated ultrasonography in
suspicious patients [10].
Treatment
EP is a major event in a woman’s reproductive life and is
particularly tragic after a long and difficult course of treat-
ment for infertility. Counselling and psychological support
should also be given alongside clinical treatment if EP
occurs, especially following infertility treatment [129].EP/HP can be treated surgically, medically and occasion-
ally by observation alone. Treatment must be customised
to the clinical condition and future fertility requirements
of the patient. However, the use of conservative ap-
proaches necessitates early diagnosis of EP/HP [130,131].
Surgical treatment
The traditional treatment for tubal pregnancy is laparot-
omy and salpingectomy. Laparoscopic approaches became
more widely accepted after the development of video lapar-
oscopy and the publication of the first series of successful
use of laparoscopy for the treatment of EP in the 1980’s
[132]. Laparoscopic surgery is the preferred approach in
haemodynamically stable patients and has largely replaced
the need for laparotomy due to improved postoperative re-
covery time and reduced morbidity [133,134].
Laparotomy is the preferred technique when the patient
is haemodynamically unstable, if the surgeon has not been
trained in laparoscopy or if laparoscopic surgery equip-
ment is not available [133-135]. There is no difference in
subsequent reproductive outcome between these surgical
approaches. However, there is a trend towards higher rates
of persistent trophoblast associated with laparoscopic sur-
gery for EP [133-136].
Salpingectomy is preferable for tubal pregnancy in pa-
tients with uncontrolled bleeding, extensive tubal damage
or recurrent EP in the same tube. Salpingostomy is indi-
cated where the patient is haemodynamically stable, wishes
to conserve her fertility, if there is an unruptured EP < 5 cm
in diameter and, especially, when the contralateral tube is
absent or damaged [134,137].
Two RCTs have compared salpingectomy and salpingos-
tomy and have recently been published (DEMETER and
ESEP). Both reported on reproductive outcomes after
treatment of EP by both techniques [137,138]. Subsequent
fertility, recurrent EP and IUP rates were similar following
both approaches. However, persistent trophoblastic tissues
were more common with salpingostomy with a relative
risk of 15 (95% CI: 2.0-113.4) for persistence [137].
Hence, Mol et al. (2014) have suggested that salpingec-
tomy should be the procedure of choice in women with
tubal pregnancy and a healthy contralateral tube. These
recommendations are also adapted by NICE in their
guidelines for the management of EP [139]. Furthermore,
a study that investigated the preference of patients regard-
ing the type of operation found out that the majority of
women preferred salpingectomy to avoid the possibility of
another EP. However, the risk of persistent trophoblast
was acceptable for these women if compensated by a small
increase in the chances of an IUP following surgery [140].
Medical treatment
Medical management for EP requires effective early diag-
nosis as its success is inversely correlated with the level of
Table 2 Criteria of methotrexate (MTX) treatment for
ectopic pregnancy (EP)
MTX for EP
Indications • Haemodynamically stable patients
• Minimal or no symptoms
• Serum hCG is < 5000 IU/L
• Ectopic mass < 3.5 cm
• No embryonic cardiac activity
• Confirmed diagnosis of ectopic pregnancy
• Able to comply with the follow-up
Contraindications • Hemodynamically unstable
• Suspected ruptured EP
• Heterotopic pregnancy
• Pregnancy of unknown location
• Breastfeeding
• Chronic liver disease
• Renal disease
• Active peptic ulcer or colitis
• Active pulmonary disease
• Immunodeficiency
• Haematological disease
• Sensitivity to MTX
• Unable to comply with visits and follow-up
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be used for the treatment of EP, including methotrexate
(MTX), potassium chloride (KCl) and hyperosmolar
glucose [130,144,145]. The advantages of medical treat-
ment are the avoidance of anaesthesia, surgery and its
complications, preservation of tubal patency and function,
and possibly cost effectiveness [130,145].
MTX, a cytotoxic drug that destroys rapidly dividing
trophoblastic cells, is the most popular medical agent for
the treatment of EP. MTX is a folic acid antagonist with
metabolism and excretion in the liver and kidney, respect-
ively [146,147]. MTX is given as single or multiple doses.
The variable dose regimen, which consists of 4 injections,
involves the addition of a reduced form of folate, citro-
vorum, to block the effect of MTX and to prevent adverse
effects on other tissues [130,147]. Another treatment
protocol with two doses of MTX and a schedule for
follow-up for the patient similar to the ‘multiple doses’
regimen was first proposed in 2007. This protocol does
not need the addition of citrovorum for the prevention of
the drug side effects [143].
The dose of MTX is calculated according to body sur-
face area (50 mg/m2) or body weight (1 mg/kg). For most
women this will be between 75 and 90 mg [146,147].
MTX can be administered by intravenous or intramuscu-
lar injection, or by local injection under the guidance of
either ultrasound or laparoscopy [141,147]. There is a
significant risk of tubal rupture in unsuccessful cases
following the use of MTX. Other side effects include
abdominal pain due to tubal abortion, stomatitis and
diarrhoea, hCG concentrations may rise for up to three
days after MTX even in successful cases, and some may
need a second dose of MTX [130,147].
Criteria for the use of MTX treatment in EP according
to ACOG and NICE guidelines are listed in Table 2.
Briefly, methotrexate can be used in haemodynamically
stable patients with minimal or no symptoms and who
have initial serum hCG concentrations < 5000 IU/L and
EP size < 3.5 cm [130,139]. Patients should be advised to
avoid sexual intercourse during treatment, becoming
pregnant for 6 months post treatment and excessive ex-
posure to sunlight and alcohol [147].
The treatment with MTX continues until hCG falls by
15% from its peak concentration within two days for single
dose regimen or between day 4 and 7 for the multiple
dose/two dose regimens [142,143,146,147]. A serum hCG
measurement is performed on day 4 and 7 and a further
dose is given if levels have failed to fall by more than 15%
in the multiple dose/two doses regimens [142,143]. Ap-
proximately 50% of the treated patients will not require
the full 4 doses in the ‘multiple dose’ protocol [130,147].
Several studies have compared laparoscopic salpingos-
tomy with MTX, finding MTX to be almost as effective
as surgery in terms of success rates and future fertilityoutcomes [135,136,138]. Tubal patency was documented
by hysterosalpingography in 78% of cases and in 65% of
patients who attempted to conceive again. Additionally,
the incidence of recurrent EP was relatively low (12%)
and was not significantly different from the observed
rate (9%) with salpingostomy [138].
A meta-analysis reported that the success rate of
MTX treatment was 92.7% and 88.1% for ‘multi-dose’
and ‘single dose’, respectively. The failure rate of ‘single
dose’ protocol was estimated to be about 3 times higher
than the ‘multiple dose’ regimen and the possibility of
tubal rupture cannot be excluded even with falling hCG
levels [148]. Signs of treatment failure or suspected rup-
ture are indications to stop medical treatment and to shift
to surgical management. Signs include haemodynamic
instability, increasing abdominal pain regardless of
trends in hCG levels, and rapidly increasing hCG con-
centrations (>53% over 2 days) after two doses or four
doses in the ‘single’ and ‘multiple-dose’ regimens, re-
spectively [138,143,149-151].
The use of MTX in women with a viable IUP is abso-
lutely contraindicated as the drug would cause miscarriage
or congenital malformations [130,152,153]. Hence, women
with a pregnancy of unknown location (PUL) or HP fol-
lowing IVF-ET should be managed by other means [130].
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treatment of EP. Sonographically guided local injection
of KCl into the heart of the ectopic fetus can induce car-
diac asystole with resolution of EP [154,155]. Hyperosmo-
lar glucose can also be injected into the gestation sac
causing local dehydration, necrosis of the trophoblastic
tissue and resolution of EP [156,157]. These agents are not
associated with fetal malformation but careful consider-
ation should be given before use of hyperosmolar glucose
since high doses could increase the risk of bleeding [158].
Recently, two studies have shown that the combination
of gefitinib, an orally active epidermal growth factor re-
ceptor inhibitor, in combination with a single dose of
intramuscular MTX (50 mg/m2) for the treatment of
tubal (n = 12) and non-tubal (n = 8) EP was safe and as-
sociated with a faster time of EP resolution by 34% com-
pared with MTX alone [145,159]. The new drug at a
daily single dose of 250 mg for seven days was well toler-
ated by the patients with mild to moderate side effects
(e.g. acne/rash and diarrhea) that are known to be asso-
ciated with gefitinib [145,159]. However, gefitinib should
only be used for a short and limited 7 days course and
women with significant pulmonary comorbidities and
Japanese ethnicity should be excluded to decrease/elimin-
ate the risk of interstitial lung disease during the treatment
of EP with gefitinib [145,159]. RCTs are still needed to
confirm the aforementioned findings about the efficacy
and safety of combining gefitinib with MTX for the treat-
ment of EP [160].
Expectant management
When serum hCG is below the discriminatory zone and
there is no intra- or extrauterine pregnancy detected by
TVS, the pregnancy can be described as being PUL
[121,150]. Several studies have reported that 44-69% of
PUL resolve spontaneously [161,162] and 8.7–42.8% of
PUL will eventually be diagnosed as early EP which were
too small to visualise on initial ultrasound scan
[112,114,163].
Expectant management is an option for clinically
stable women with serum hCG levels below the discrim-
inatory zone, minimal symptoms associated with either
PUL or EP diagnosed on ultrasound [161,164,165]. Re-
cent results from an RCT study showed that there is no
significant difference in the outcome between MTX and
expectant management groups in suitable patients [165].
Another Australian research group announced recently
the initiation of a double-blinded multicentre RCT to
compare between medical and expectant management
for EP but the results has not been published yet [166].
Patients with EP may have an initial 50-66% increase in
β-hCG concentrations every two days [112,165], mimick-
ing a viable IUP. However the eventual fate of EP is either
spontaneous resolution or rupture. This is dependent onthe activity of the invading trophoblast tissue, with less
aggressive invasion of the trophoblast tissue being asso-
ciated with spontaneous resolution and more aggressive
invasion leading to tubal rupture [167,168]. If the
serum hCG concentrations increase, intervention is es-
sential or the patients may suffer ruptured EP. On the
other hand, for patients at an early stage, with lower
gestational age and declining β-hCG titres, the risk of
rupture is small [161,165].
Regular follow-up is essential if expectant management
is to be successful and clear information about the im-
portance of compliance with follow-up should be given
to the patient. Serial serum hCG concentrations should
be followed until they reach < 15 IU/L. If symptoms and
signs of EP develop, serum hCG concentrations rise
above discriminatory zone or start to plateau, active
intervention should be considered [164,165].
Management of heterotopic pregnancy
The clinical management of HP aims to remove the EP
without disturbing the viable IUP. Currently, there is no
general consensus on the treatment of HP and the major-
ity of data about its clinical management derive from case
reports. Surgical treatment by laparotomy or laparoscopy,
injection of feticides with or without fetal reduction by
embryo aspiration under ultrasound guidance and expect-
ant management have all been used and reported to be
successful in the elimination of the ectopic and preserva-
tion of ongoing IUP. The selection of treatment protocol
depends on the gestational age at diagnosis, the clinical
condition of the patient, the site of ectopic implantation
and the experience of the treating physician. In a number
of studies, the success rate for rescuing the viable IUP was
about 66% with the remainder ending in early or late mis-
carriage [108,122,169].
The treatment of HP with a tubal implantation can be
performed by laparotomy or laparoscopy and the removal
of EP is usually done by salpingectomy and occasionally
by salpingostomy [170-174]. For interstitial HP, either
medical treatment with local injection of a feticide/embryo
reduction for small non-ruptured EP [158,175,176] or
cornual resection by laparoscopy or laparotomy in ruptured
cases has been used with rescue of the IUP [177-180].
A few studies have also reported the use of expectant
management for tubal and interstitial HP [181,182].
Currently, only 14 cases of caesarean scar HP are re-
ported in the literature. The majority of cases were
treated medically by local injection of feticides and/or
embryo aspiration to rescue the viable IUP except for 2
cases that were treated by laparoscopic and hystero-
scopic excision of the EP masses [169,183]. Caesarean
scar pregnancy can lead to massive haemorrhage due to
uterine rupture and laparotomy followed by wedge exci-
sion has been reported to be the preferred approach to
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tion of recurrence [169,184,185].
The majority of cases with cervical HP have been
treated conservatively using embryo aspiration with or
without local injection of a feticide to preserve the viable
IUP [186-188]. Others have successfully used laparos-
copy or hysteroscopy for the removal of cervical EP and
preservation of the IUP [189,190]. Efficacious use of ex-
pectant management with continuous close monitoring by
TVS was also reported in a few cases [141,188]. However,
dilatation and curettage was also found to be necessary in
some cases to prevent massive bleeding from cervical
pregnancy [141,188].
Ovarian HPs have been managed by wedge resection
using laparoscopy or by laparotomy in cases of massive
bleeding [191]. Other cases have resulted in salpingo-
oophorectomy due to massive adhesions from a rup-
tured EP [192]. Other ectopic sites within the abdominal
cavity have also been reported and have been treated
surgically due to bleeding.
Anti-D immunoglobulin
According to NICE guidelines, anti-D immunoglobulin
at a dose of 250 IU should be given to all non-sensitized
women who are rhesus negative and who have EP [139].
Complications of ectopic/heterotopic pregnancy
Persistence of trophoblastic tissue
Persistent trophoblast can follow either laparoscopic
or open salpingostomy with reported incidences of
8.1% and 4%, respectively [26,137,193,194]. Risk factors
for persistent trophoblastic tissue include high pre-
operative serum hCG (>3000 IU/L), a rapid preopera-
tive rise in serum hCG and the presence of active tubal
bleeding [135,136]. Failure of serum hCG concentra-
tions to decline following initial management is the
main diagnostic sign [135,194].
There is no common protocol for the early diagnosis
and initiation of treatment of persistent trophoblast [194].
Some have recommended second line treatment if the
serum hCG is greater than 10% of the preoperative level
ten days after surgery while others have suggested starting
treatment if serum hCG concentrations are > 65% of their
initial levels at 48 hours after surgery. Treatment with a
single dose (50 mg/m2) of MTX has been widely used as
an alternative to a second surgical procedure. One RCT
compared the use of prophylactic MTX at the time of lap-
aroscopic salpingostomy with simple salpingostomy alone
and showed a reduction in the rate of persistent tropho-
blast by 19% and 14%, respectively [135].
Complications associated with heterotopic pregnancy
Miscarriage of the viable IUP can follow treatment of a
HP. Clayton et al. reported that 84 (40.6%) out of 207heterotopic cases ended with abortion either spontan-
eously or induced [195]. HP was 30% less likely to result
in live-birth than an intrauterine only pregnancy follow-
ing IVF treatment mainly due to the increase in risk for
spontaneous and induced abortion in HP by 2 and 10
times compared with singleton IUP, respectively [195].
It is not known whether there is a difference in mis-
carriage rate between the different types of HP mainly
due the rarity of the condition. However, early diagnosis
and use of conservative approaches should lead to a bet-
ter chance of live birth of the co-existing IUP. Hence, a
more common site of ectopic implantation (e.g. tubal)
may have a better prognosis compared with less frequent
sites (e.g. caesarean scar). Future studies are needed to
allow comparison of outcomes between the different
sites of ectopic implantation and/or different treatment
approaches, possibly using a large retrospective survey
of IVF registries.
HP can result in complications including severe
bleeding and hypovolemic shock, preterm delivery,
uterine rupture in cases with caesarean scar implant-
ation or oophorectomy in cases of complicated ovarian
implantation [108,173,183].
Effect of ectopic pregnancy and its treatment on
subsequent IVF treatment
The effects of the different lines of treatment for EP, espe-
cially radical and medical managements, on subsequent
IVF have been described. The significance of salpingec-
tomy in the outcome of subsequent IVF-ET is controver-
sial. It was suggested that salpingectomy could have an
adverse effect on ovarian blood supply and subsequently
on ovarian steroid production, further follicular develop-
ment and ovarian response during later IVF cycles due to
the disturbance of the vascular and neural connections be-
tween the Fallopian tube and ovary [196,197]. Many inves-
tigators reported significantly fewer follicles and oocytes
either from both ovaries or the ipsilateral ovary following
salpingectomy [196,198-201].
However more recent retrospective studies that have
measured parameters of ovarian response in women who
underwent ovulation induction before and after salpingec-
tomy have shown no significant difference in basal FSH
levels, oestrogen concentrations, length of stimulation,
number of follicles, number of retrieved and fertilised
oocyte and quality of embryos between the pre- and post-
salpingectomy cycles [202-206].
Results about the requirement for gonadotropins for su-
perovulation are also conflicting. While two studies
showed no significant difference [202,207], another de-
scribed a significant increase in the doses needed following
surgery [203]. Ye et al. also reported that serum concen-
trations of anti-Mullerian hormone were significantly
lower and FSH were significantly higher in patients with
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However there were no significant differences in peak
oestradiol concentration, endometrial thickness, number
of retrieved oocytes or pregnancy rate between the study
groups [207].
Surgical treatment of an EP may result in oophorec-
tomy, either because of an advanced ovarian pregnancy
or when tubal pregnancy forms a tubo-ovarian mass due
to the presence of extensive pelvic adhesions [192,208].
Women with a single ovary represent a distinct treatment
group when ART is needed. Many studies have shown
that women who have undergone unilateral oophorectomy
respond less well to ovarian stimulation than women with
both ovaries, in terms of number of follicles, oestradiol
concentrations and number of oocyte retrieved [208-214].
These women also seem to require a higher dose of
gonadotropins in order to obtain an adequate ovarian
response [208,211,214]. However, pregnancy rates in
these women were similar to those with intact ovaries
in the majority of these studies.
Interestingly, a very recent study has reported that
despite the observed overall decrease in the number of
follicles and oocytes retrieved seen in women with a sin-
gle ovary, it appears that the remaining ovary is able to
compensate. This was indicated by an increase in the
number of follicles and oocytes obtained in patients with
a single ovary compared with the response of the ipsilat-
eral ovary of control women during IVF treatment [215].
It appears therefore, that once women with single ovary
reach embryo transfer, they can be reassured that their
chance of having a child is the same as for women with
two ovaries.
MTX is the most accepted alternative to surgical treat-
ment of EP and it was thought that it could potentially
compromise female fertility by affecting growing follicles
[216,217]. However, it appears that the cytotoxic agent
does not have any harmful effect on ovarian reserve as
primordial follicles in the ovaries are not affected follow-
ing treatment with MTX [218-222]. Additionally, there
was no significant difference in the ovarian reserve in
subsequent IVF cycles between women treated with lap-
aroscopic salpingectomy and those treated with MTX
[206,222,223]. Hence, it is reassuring to show that the
effects of MTX, after it is used as a medical treatment
for an EP, does not affect or further compromise a
woman’s future reproductive potential [206,222,223].
Conclusions
Ectopic pregnancy is a worldwide medical emergency and
its incidence increases following treatment of infertility.
Heterotopic pregnancy is also more common following
IVF-ET. Early diagnosis and prompt intervention are cru-
cial in order to diminish the morbidity and mortality of
EP/HP. The combination of TVS and quantitative serumhCG is currently the most reliable diagnostic tool. Consid-
ering the increase risk of EP/HP subsequent to IVF-ET,
follow-up of those patients with a positive pregnancy
through early pregnancy is vital and the performance of
TVS between weeks 4 and 6 of gestation could allow early
detection and conservative management.
Patients with PUL should be closely monitored by serial
measurement of serum β-hCG and repeated ultrasonog-
raphy. The finding of empty uterus by TVS and persistent
increase in hCG concentration should trigger an estab-
lished protocol for detection of EP. Heterotopic gestation
presents a particular diagnostic challenge since the diag-
nostic value of hCG is limited due to the co-existing viable
IUP. The detection of a HP requires a high index of suspi-
cious coupled with TVS by an experienced operator.
Treatment approaches should be tailored according
the clinical condition and future fertility requirement of
the patient and they should be offered alongside with
psychological support. The patient should also be pro-
vided with accurate and reliable information on risks of
the different treatment approaches and their associated
complications and be reassured about the preservation
of prospective fertility in subsequent IVF-ET cycles.
New diagnostic tests are needed to better identify those
who are at highest risk of developing EP during assisted
conception. Special measures might then be adopted in
order to avoid this complication, for example by elective
salpingectomy or tubal clipping at the cornu as is prac-
tised for women with hydrosalpynx. Although the majority
of cases can be quickly diagnosed using existing methods,
diagnostic dilemmas in the form of PUL or suspected HP
still present challenges to the reproductive medicine spe-
cialist. Improvement in ultrasound diagnosis of early em-
bryonic localisation and viability, perhaps coupled with
novel diagnostic tests for the presence of an extra uterine
pregnancy will make the clinicians job easier in the future.
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